Stealth Biotech identified five metabolites, age, body mass index, and renal function as predictors of 12-month progression-free survival using a multimodal machine-learning framework integrating 154 metabolites with clinical variables.
Public source
Publisher name
Public post
To histidine, or not to histidine. The projection of medical prognosis demands reliable parameter. Metabolic analyses offers a contributing capacity. … histidine it is.…
Company
Stealth Biotech
Coming soon
- Industry
- Biotechnology Research
- Company size
- 51–200 employees
About Stealth Biotech
A stealth mode biotech startup located in San Mateo county, CA.
See moreLatest activity
Latest activity from Stealth Biotech
6 signals
Research & Knowledge
Stealth Biotech published recent clinical findings showing that some individuals diagnosed with relapsing-remitting multiple sclerosis (MS) can benefit from anti-CD20 B cell therapies, indicating a potentially pathogenic role for autoreactive B cells.
Research & Knowledge
Stealth Biotech profiled 4,336 plasma samples from 1,714 patients across five tumor types and 16 cohorts spanning Europe and North America, longitudinally sampled during five immune-checkpoint inhibitor-based treatment modalities, including fecal microbiota transplantation.
Research & Knowledge
Stealth Biotech found that histidine-rich diets improved progression-free survival in patients lacking dysbiotic microbiome signatures associated with histidine catabolism.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Olaris, Inc
Olaris, Inc uses analytical tools to capture metabolite signals on a larger scale to reveal what is happening in disease.
Research & Knowledge
Cure51
Cure51 published a Rosalind Study combining multiple layers of patient data, including genomics, transcriptomics, pathology, clinical history, and multi-omics insights, to integrate complex datasets and identify patterns for AI-driven treatment prediction.
Research & Knowledge
Crown Bioscience
Crown Bioscience conducted a multi-omic comparison of preclinical cancer models, integrating transcriptomic, proteomic, and genomic data from over 10,000 primary tumors and nearly 4,000 preclinical models.
Research & Knowledge
1Cell.Ai Inc.
1Cell.Ai Inc. published a study in Cancer Research, an AACR Journals, highlighting the potential of comprehensive ctDNA profiling in treatment-naïve patients with early-stage breast cancer.
Research & Knowledge
PanGIA Biotech, Inc.